At the NRG Oncology Summer Meeting on Thursday, July 20, 2023, at approximately 5:44 pm EST, Larry J. Copeland, MD passed the presidential gavel to Thomas J. Herzog, MD at The GOG Foundation, Inc. (GOG-F) Board of Directors meeting.

Dr. Herzog brings a comprehensive background in clinical trials, the integral business aspects and acumen to this important position. A practicing gynecologic oncologist and member of the Board of Directors of GOG-F, he has served as the Treasurer of GOG-F from 2014-2023 and prior to taking presidential office, served as Associate Director of the GOG Partners (GOG-P) program. He is currently Deputy Director of the University of Cincinnati Cancer Center and Paul & Carolyn Flory Professor in the department of Obstetrics and Gynecology at the University of Cincinnati. Dr. Herzog has authored/co-authored over 325 peer-reviewed articles and lectures extensively nationally and internationally. He serves and has served on the editorial boards of *Gynecologic Oncology*, *Obstetrics and Gynecology International*, *Hematology Oncology Times*, and others. He served as Editor-In-Chief of *Women’s Oncology Review* and *Gynecologic Oncology Research to Practice*. Dr. Herzog has also served on the board of directors or leadership council of the Society of Gynecologic Oncology, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology-Gynecologic Oncology Division, and the International Gynecologic Cancer Society.

Dr. Herzog will be responsible for GOG-F, which includes the GOG Foundation corporate membership in the NRG Oncology Foundation, Inc., and GOG-P program. The GOG-F, formerly known as
the Gynecologic Oncology Group, in collaboration with the NSABP Foundation, Inc. and the RTOG Foundation, Inc., formed a new 501(C)(3), in 2012, NRG Oncology Foundation, Inc. (NRG). In addition to the NRG responsibilities, Dr. Herzog will also oversee the GOG Partners program founded in 2013 and work alongside Dr. Robert Mannel, Senior Vice President of GOG-F. Dr. Mannel is also one of the Group Chairs that is responsible for the research conducted by the NRG Oncology clinical cooperative group that is a member of the NCI National Clinical Trials Network.

Dr. Herzog shares, “It is truly an amazing honor to be the next President of The GOG Foundation. I am cognizant of the need to ever improve our organization to face the challenges of maintaining our role as the premier clinical trials network in gynecologic malignancies in North America and beyond. Initiatives in diversity, operational transparency, translational research, site expansion, and improved trial efficiencies are ongoing, and will be further developed moving forward. In addition, I look forward to training our next generation of outstanding clinical trialists. Following a true legend like Dr. Copeland is not easy, but I pledge to honor the principles that he and Dr. DiSaia so effectively instilled in our group as tremendous leaders in our field. I look forward to Dr. Copeland’s continued involvement, wisdom, and guidance through his role as Immediate Past President. I have incredible confidence and trust in the ability of the amazing GOG-F physician leadership and staff teams to effectively navigate our path forward in transforming the standard of care for our patients afflicted with gynecologic malignancies.”

Click here to view the full press release.

IGCS PRESIDENT HONORS DR. LARRY COPELAND AS HE STEPS DOWN AS GOG PRESIDENT

Dear Members and Friends,

My long-time mentor, friend, and colleague, Prof. Larry J. Copeland has recently stepped down as President of the GOG Foundation (GOG-F) —a position he has held since 2017. I wanted to take a moment to congratulate and recognize his contributions to the subspecialty and to personally express my gratitude for his mentorship and friendship over the years.

Early in my career, it was through my involvement with the GOG and other clinical trials groups such as GCIG, JGOG, and GOTIC, that I was introduced to evidence-based medicine and connected to the global community of investigators. I teach my students that clinical trials provide the highest level of evidence and that being involved in clinical trials is a way to improve their level of daily practice in a number of ways. This is exactly what I have learned
Larry and I have had many interactions over the span of our careers and I’m glad to not only be able to call him my teacher, but also a friend.

The GOG Foundation is a key partner for the IGCS, strengthened even more this year through our strategic partnership in which the GOG-F has taken on the role as the preferred educational provider for Industry Supported Symposia, starting at the 2023 IGCS Annual Global Meeting.

Larry will continue to serve as Immediate Past President as Dr. Thomas Herzog steps into the role of President. I wish them both the best and know that the future of the organization is in good hands, building on the successes of the past.

Click here to view the full statement.

INCLUSION, DIVERSITY, EQUITY, AND ACCESS (IDEA)
IN GYNECOLOGIC CANCER CLINICAL TRIALS:
A JOINT STATEMENT FROM GOG FOUNDATION AND SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO)

Clinical research is the key to advancing knowledge in patient care, whereby discovery of novel treatments can improve outcomes\textsuperscript{1}. Within oncology, clinical trials can improve prevention, screening, treatment, and/or survivorship strategies. Many clinical trials offer access to novel agents that may become the new standard with the goal of improving outcomes and/or reducing treatment-related adverse events. While these discoveries are intended to improve oncologic outcomes for all, individuals from diverse ethnic and racial groups who have the highest need for improved cancer care are underrepresented in clinical trials. Race refers to a set of physical characteristics that is a social, political, and economic construct, without biologic basis. Ethnicity describes a shared culture, heritage, religion, language, and customs within a geographic region; there may also be shared genetic and genomic commonalities. Health disparities are related to the societal legacy of structural racism and its sustained impact on present day practices and policies, which perpetuate diminished opportunity for at-risk populations.
IN MEMORY OF

It's with great sadness that we share the details of our friends and colleagues that have recently passed.

**Wendy Rosamund Brewster, MD, PhD**
**May 24, 1966 - July 24, 2023**

Dr. Wendy Rosamund Brewster was born May 24th, 1966 in Newcastle upon Tyne, United Kingdom and died July 24th, 2023 in Bellaire, Texas. She attended Queen’s College high school in Georgetown, Guyana from 1977 -1983 and received a Bachelor of Science degree from Rutgers University, New Jersey in 1987, graduating Phi Beta Kappa. Wendy went on to receive her medical degree from the University of California, Los Angeles (UCLA) and her PhD in Epidemiology from the University of California, Irvine (UCI). She completed a residency in obstetrics and gynecology at Harbor-UCLA Medical Center and a fellowship in gynecologic oncology at UCI, joining the faculty in 2000. In 2008, she joined the faculty at the University of North Carolina (UNC), Chapel Hill where she rose to a Professor with Tenure in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. Wendy was Director of the UNC Center for Women’s Health Research, co-chair of the UNC Lineberger Comprehensive Cancer Center Equity Council and held an adjunct position of Professor in the Department of Epidemiology in the Gillings School of Global Public Health, Chapel Hill.

[Click here](#) to read the full obituary.

---

**David Samuel Alberts, MD**
**December 30, 1939 - July 29, 2023**

Dr. David Samuel Alberts passed away on July 29, 2023, after a courageous battle with Parkinson's Disease.

David Graduated with honors and distinction from UVA medical School in 1966 and went on to pursue a career in Oncology. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers. Alberts authored or co-authored over 550 peer reviewed publications and 100 book chapters and served as Editor of nine books. Dr. Alberts conducted his internal medicine residency at the University of Minnesota and then served on the faculty of the University of California, San Francisco, for five years and
obtained Board certification in Medicine and Medical Oncology in 1973. He joined the UArizona College of Medicine in 1975 as a professor, where he has served for over 48 years and served as the UArizona Cancer Center Director from 2005 to 2013. Dr. Alberts was a Regents Professor of Medicine, Pharmacology, Nutritional Science, and Public Health at the UArizona College of Medicine. Dr. Alberts retired from full time work in 2017, however, that could not keep him away from his passion of curing Women's cancers. He continued to work part time at UACC. While Dr. Alberts will be remembered for his dedication to cancer research and development of new oncology drugs and treatments, his biggest impact will be on the lives he touched and saved as an outstanding physician.

Click here to read the full obituary.

SGO, FWC and GOGF Receives ASCO Endorsement on Joint Guidelines for Gynecologic Cancer Drug Shortage

Currently, a U.S. shortage of carboplatin and cisplatin exists that will likely last several months or longer. SGO, FWC, and GOGF give joint guidelines on how we can conserve carboplatin and cisplatin and allocate the limited supply to those patients who will experience the most significant benefit.

Click here to learn more about these guidelines.

FEATURED CLINICAL TRIALS

GOG-3031 RUBY PRESS RELEASE

Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

July 31, 2023: GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H). The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the
Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression. In the RUBY trial, Jemperli plus chemotherapy demonstrated a 71% reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit. These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”

Click here to view the full press release.

GOG-3047 KEYNOTE A-18 PRESS RELEASE

KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

July 19, 2023: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) met one of its primary endpoints of progression-free survival (PFS) as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer. At a prespecified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent chemoradiotherapy showed a statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone.

A favorable trend in overall survival (OS), the trial’s other primary endpoint, was also observed for KEYTRUDA plus concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone; however, these OS data were not mature at the time of this interim analysis. The trial is continuing and follow-up of OS is ongoing. The safety profile of KEYTRUDA in this trial was
consistent with that observed in previously reported studies; no new safety signals were identified. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Click here to view the full press release.

---

RAMP 301 PRESS RELEASE

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

**July 5, 2023:** Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has finalized with the U.S. Food and Drug Administration (FDA) the design of its confirmatory Phase 3 trial to evaluate the combination of avutometinib and defactinib for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). RAMP 301, a randomized global confirmatory trial, will evaluate the efficacy and safety of avutometinib and defactinib versus standard of care (SOC) chemotherapy and hormonal therapy in patients with recurrent LGSOC. RAMP 301 is expected to begin enrollment in the second half of this year.

RAMP 301 is the follow-up confirmatory study for full approval in recurrent LGSOC. The Company intends to file for Accelerated FDA Approval for the combination of avutometinib and defactinib based on mature data from the Company’s Phase 2 registration-directed RAMP 201, together with the results of the investigator-initiated FRAME trial. The Company recently reported results of Part A of RAMP 201 including confirmed objective response rates (ORR) by blinded independent central review of 45% (13/29; 95% CI: 26%, 64%) with a tolerable safety profile.

Click here to view full press release.

---

GOG-3041 (DUO-E) | ENGOT-EN10 PRESS RELEASE

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

**May 26, 2023**
Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer. There was a greater clinical benefit observed with the combination of Imfinzi and Lynparza as maintenance treatment.

Overall survival (OS) data were immature at the time of this analysis however, a favourable trend was observed for both treatment regimens.

Endometrial cancer is the 6th most common cancer in women worldwide, with over 417,000 patients diagnosed and over 97,000 deaths in 2020. Diagnoses are expected to rise by almost 40% by 2040. The current standard of care for advanced endometrial cancer is chemotherapy. However, long-term outcomes in 1st-line endometrial cancer remain poor and novel treatment options are needed.

Shannon N. Westin, Professor of Gynaecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center, and principal investigator of the DUO-E trial, said: “These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further. These combinations could provide physicians with new treatment approaches to improve outcomes for patients.”

Click here to view the press release.

---

**GOG-3052 (RAMP 201)**

**PRESS RELEASE**

**Updated Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib**

**May 25, 2023:** In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients. Safety and tolerability continued to be favorable and consistent with previously
reported data. These data, which will be presented at the American Society of Clinical Oncology Annual Meeting, build on the Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration (FDA) for the combination in recurrent LGSOC.

RAMP 201 is an international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent LGSOC. The key objectives of Part A (Selection Phase) of the RAMP 201 LGSOC study were to select avutometinib monotherapy or the combination of avutometinib and defactinib as the go forward regimen to be studied in Part B (Expansion Phase) of the study, and to assess efficacy in both KRAS mutant and KRAS wild type LGSOC. These data reinforce the selection of the combination of avutometinib (3.2 mg PO twice weekly 21/28 days) with defactinib (200 mg PO BID 21/28 days) as the go forward regimen regardless of KRAS status, and target enrollment has been achieved in both Part A and Part B.

Click here to view the press release.

GOG-3082 (ACR-368-201)

PRESS RELEASE

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

May 9, 2023: Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer. Fast Track designation is intended to facilitate the development and expedite the review of promising investigational drugs to treat serious conditions with significant unmet medical needs. A drug candidate that receives Fast Track designation can be eligible for Accelerated Approval and Priority Review, and often have the opportunity to communicate more frequently with the FDA on trial design and data, among other benefits if relevant criteria are met.

One Fast Track development program designation was granted for the
investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature® positive, locally advanced, or metastatic, recurrent platinum-resistant high-grade ovarian carcinoma who have received at least one prior systemic treatment regimen. The second Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic treatment regimens.

Click here to view the full press release.

SPECIAL RECOGNITION

International Gynecologic Cancer Society Announces Inaugural Uterine Cancer Awareness Month

The International Gynecologic Cancer Society (IGCS) in collaboration with over 25 partner organizations from around the world, today announced June as the inaugural Uterine Cancer Awareness Month. The observance is part of a global initiative led by the IGCS to raise awareness about uterine cancer (also called endometrial cancer) and promote the need for further research funding, community education, and equitable access to high-quality care. The IGCS is supported in this initiative by advocacy groups around the world, including the Endometrial Cancer Action Network for African Americans (ECANA), Facing Our Risk of Cancer Empowered (FORCE), SHARE, and the Uterine Cancer Awareness Network (UCAN), among others.

Click here to read the full Press Release

UPCOMING INDUSTRY MEETINGS

ESGO 2023 Congress
The ESGO 2023 Annual Meeting will be held **September 28 - October 1, 2023** in Istanbul, Türkiye.

ESGO congress offers professionals in Gynaecological Oncology - including clinicians, researchers, residents and students a unique opportunity to learn and discuss the latest medical and scientific developments in gynaecological cancers research, treatment and care, as well as to network with key opinion leaders and peers from around the world.

[Click Here](#) to register to attend.

---

**ESMO Congress 2023**

The ESMO Congress 2023 will be held **October 20 - 24, 2023** in Madrid, Spain.

ESMO 2023 will disseminate the latest cutting-edge data, provide high quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.

[Click here](#) to register to attend.

---

**IGCS 2023 Annual Global Meeting**

The Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2023) will be held from **November 5 – 7, 2023** in Seoul, South Korea.

Join us in Seoul and connect with colleagues from all over the world at the largest international meeting dedicated to women's cancers.

[Click here](#) to register to attend today!

---

**ON DEMAND EDUCATION**

The GOG Foundation, Inc. is thrilled to share the following Industry Supported Symposium Enduring Educational Materials from the June 2023 GOG Highlight Reel 2023 and the 2023 SGO Annual Meeting on Women’s Cancer®.

Visit the links below to view these exciting sessions available today!
The GOG Highlight Reel - June 2023

**Access to Symposium Recording**
Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the GOG Highlight Reel – June 2023 recording.

**Access to Symposium Presentations**
Please [click here](#) to access the individual presentation files on the GOG website.

---

2023 SGO Annual Meeting on Women’s Cancer®

- [Click here](#) to view the symposium: Novel combinations, biomarkers and immune modulators to overcome platinum resistance in recurrent ovarian cancer (PROC)
- [Click here](#) to view the symposium: Patient Management: Engaging the care team to provide new treatment opportunities with an ADC in recurrent metastatic cervical cancer

---

**CLINICAL TRIALS**

The GOG Partners Program is currently recruiting for 20 clinical trials

- 13 Ovary
- 1 Cervix
- 6 Endometrium

To search active trials visit our website by clicking Clinical Trials button below.

---

**PHILANTHROPY**

**New Horizons Gynecologic Cancer Research Fund**

The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for The GOG Foundation, Inc. Donations allow the GOG to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research
Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:

- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

---

**LET’S GET SOCIAL**

**What GOG Means to ME**

“GOG means research success and amazing people. GOG runs trials that provide novel effective treatments for patients with gynecologic malignancies. GOG is inclusive in mentoring our next generation of clinical trialists to be the best.”

Thomas J. Herzog, MD
GOG Partners Associate Director
Clinical Director
Paul & Carolyn Flory Professor in Gynecologic Oncology
University of Cincinnati

---

**Become a GOG Social Media Agent**

The GOG Foundation is looking for members that are savvy with social media to become GOG Social Media Agents! Throughout the year our communications staff will invite our agents to participate in social media campaigns for meetings, education and special events. If
(Twitter, Instagram, LinkedIn and Facebook). If you would like to participate, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- **Quote**: No more than 35 words indicating what GOG means to you, examples can include: research, clinical trials, networking.
- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags**: Please provide how we can find you on each of the social platforms so we can tag you when we post.

If you are interested in becoming a GOG Social Media Agent, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags**: Please provide how we can find you on each of the social platforms so we can tag you when we post.

---

**How Can We Help?**

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.

---

GOG Foundation Inc. | Four Penn Center, 1600 JFK Blvd. Suite 1020, Philadelphia, PA 19103

Unsubscribe cgaloppo@gog.org
Update Profile | Constant Contact Data Notice
Sent by lmoeller@gog.org powered by

---

Try email marketing for free today!